Zepzelca
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small-cell Lung Cancer
Conditions
Extensive-stage Small-cell Lung Cancer
Trial Timeline
Jun 28, 2021 → Jun 4, 2025
NCT ID
NCT04894591About Zepzelca
Zepzelca is a pre-clinical stage product being developed by Jazz Pharmaceuticals for Extensive-stage Small-cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04894591. Target conditions include Extensive-stage Small-cell Lung Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04894591 | Pre-clinical | Completed |
Competing Products
20 competing products in Extensive-stage Small-cell Lung Cancer